08:00 , Nov 29, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Aurora kinase B (AURKB; aurora-B) In vitro and mouse studies identified an AURKB-specific inhibitor that could...
07:00 , Oct 13, 2011 |  BC Innovations  |  Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens Assay to evaluate gene-drug interactions and predict chemotherapeutic resistance An assay to evaluate gene-drug interactions could help guide...
07:00 , Aug 26, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Aurora kinase A (AURKA; Aurora-A); AURKB (Aurora-B) An in vitro and rodent study identified phthalazine-based...
08:00 , Feb 22, 2010 |  BioCentury  |  Strategy

Roadmap to big cap

Rigel Pharmaceuticals Inc. is looking to last week's deal with AstraZeneca plc as the springboard from small cap biotech to fully functioning biopharmaceutical company. The deal provides Rigel with enough money to invest in its...
07:00 , Mar 24, 2008 |  BioCentury  |  Finance

Ebb & Flow Focus

Although big series A rounds have become increasingly commonplace, the recent deal for Albireo AB, expected to reach $40 million, reflects business as usual for Nomura Phase4 Ventures.The London firm has taken an aggressive approach...
00:27 , Nov 22, 2007 |  BC Extra  |  Clinical News

Merck suspends enrollment of MK-0457 trials

Vertex (VRTX) said partner MRK suspended enrollment in trials of MK-0457 (VX-680) after QTc prolongation was observed in one patient in a Phase II trial to treat chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute...
08:00 , Nov 19, 2007 |  BC Week In Review  |  Company News

Rigel, Merck KGaA deal

MRK's Merck Serono S.A. subsidiary exercised an option under a 2005 deal to license exclusive Japanese rights to develop and commercialize R763/AS703569 and other aurora kinase inhibitors from RIGL. Merck Serono already had...
07:00 , May 7, 2007 |  BC Week In Review  |  Company News

Vertex, J&J, Merck deal

VRTX received a $15 million milestone payment from JNJ's Janssen Pharmaceutica K.K. subsidiary under a deal that gave JNJ an exclusive license to develop and commercialize VX-950 to treat HCV in Europe, South America,...
07:00 , Apr 3, 2006 |  BioCentury  |  Finance

Ebb & Flow

Hunter-Fleming set off to a series B financing to support its neurology efforts, and now the U.K. company finds itself with much more, including a stake in a new company and a foothold in the...
08:00 , Jan 30, 2006 |  BioCentury  |  Strategy

Serono chronicles

Serono chronicles Selected events tracked against Serono's weekly stock price since the company listed on the NYSE in 2000. 1/27/00 - Exclusively licenses recombinant leukemia inhibitory factor (LIF) from Amrad (now Zenyth Therapeutics) for development in...